ArticleCureus2025
Perioperative, Functional, and Oncological Outcomes of Robotic-Assisted Partial Nephrectomy in 1,267 Indian Patients: A Multicenter Analysis by the Indian Robotic Partial Nephrectomy (IRPN) Collaborative Group.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of global experiences with Medtronic's Hugo™ robotic system for robot-assisted partial nephrectomy.Journal of robotic surgery · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRobotic-assisted partial nephrectomy (RPN) is increasingly recognized as an effective treatment for small renal masses. This study aims to highlight the therapeutic benefits of RPN for both small and relatively larger renal masses in the Indian population.
methodsA retrospective chart review was conducted on patients who underwent RPN using the da Vinci surgical system between September 2010 and September 2022 across 14 centers located in various cities of India, including Ahmedabad, Bengaluru, Chandigarh, Chennai, Delhi, Gurugram, Hyderabad, Kochi, and Nadiad. Data on demographics, medical history, clinical characteristics, and perioperative, functional, and oncological outcomes were extracted from medical records and analyzed statistically.
resultsA total of 1,267 patients were included in the study, with 757 in the T1a tumor group and 510 in the T1b+T2 tumor group. In terms of baseline characteristics, the two groups showed a significant difference (p < 0.001) in renal nephrometry score (RENAL score). The mean operating room time (201.31 ± 77.57 vs. 191.06 ± 74.51; p = 0.0021) and warm ischemia time (25.21 ± 8.08 vs. 22.51 ± 7.95; p < 0.001) were significantly higher in the T1b+T2 tumor groups. Other outcomes were comparable, namely, length of hospital stay (4.21 ± 2.47 vs. 4.05 ± 2.30 days; p = 0.2459), postoperative complications (3.33% vs. 2.11%; p = 0.181), conversion rates (0% vs. 0%), and surgical margins (3.04 vs. 4.31%, p = 0.229). There was no difference in recurrence rates, and no significant differences were observed in the functional outcomes between the two groups.
conclusionRPN provides encouraging surgical, oncological, and functional outcomes for both T1a and T1b+T2 renal masses, enabling nephron-sparing surgery and early recovery of renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.